التفاصيل البيبلوغرافية
| العنوان: |
Advances in Immunosuppressive Agents Based on Signal Pathway. |
| المؤلفون: |
Xu, Zhiqing, Chu, Ming |
| المصدر: |
Frontiers in Pharmacology; 5/26/2022, Vol. 13, p1-37, 37p |
| مصطلحات موضوعية: |
IMMUNOSUPPRESSIVE agents, EVEROLIMUS, CELLULAR signal transduction, MTOR inhibitors, ALLERGIES, AUTOIMMUNE diseases |
| مستخلص: |
Immune abnormality involves in various diseases, such as infection, allergic diseases, autoimmune diseases, as well as transplantation. Several signal pathways have been demonstrated to play a central role in the immune response, including JAK/STAT, NF-κB, PI3K/AKT-mTOR, MAPK, and Keap1/Nrf2/ARE pathway, in which multiple targets have been used to develop immunosuppressive agents. In recent years, varieties of immunosuppressive agents have been approved for clinical use, such as the JAK inhibitor tofacitinib and the mTOR inhibitor everolimus, which have shown good therapeutic effects. Additionally, many immunosuppressive agents are still in clinical trials or preclinical studies. In this review, we classified the immunosuppressive agents according to the immunopharmacological mechanisms, and summarized the phase of immunosuppressive agents. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder